Sorafenib (Sorafenat) 200mg Tablets: Building Combination Regimens for Hepatocellular Carcinoma

Overview

Sorafenib (Sorafenat) 200mg tablets hold their place in hepatocellular carcinoma care partly because they combine well with local therapies rather than standing alone. The multi-kinase inhibitor is frequently paired with transarterial chemoembolization to address both the tumor and its blood supply. For B2B oncology suppliers, the combination narrative is what sustains steady demand, since clinicians order around established multimodal protocols. The 200mg strength and 120-tablet pack align with the extended treatment courses these regimens require.

How It Works

Sorafenib blocks several receptor tyrosine kinases involved in tumor cell proliferation and in the formation of new tumor blood vessels. By dampening signaling through these pathways, it restricts both cancer-cell growth and the angiogenic feed that sustains the lesion. In combination with embolization, the systemic anti-vascular effect complements the local cutoff of arterial supply. The drug is taken orally, which keeps the regimen manageable alongside interventional procedures.

Indications

Sorafenib is indicated for advanced hepatocellular carcinoma and is also used in certain renal-cell and thyroid carcinoma settings per local labeling. It is prescribed by oncology specialists and is not a first-line option for every liver tumor. Combination with TACE is decided case by case based on liver function and disease extent. Buyers should confirm the exact registered indication for the destination market before promotion.

Dosage & Administration

The standard oral dose is 400mg twice daily, supplied as two 200mg tablets per administration, taken on an empty stomach. Treatment continues under specialist supervision with periodic liver-function and blood-pressure monitoring. The 120-tablet pack covers roughly a month of therapy at the standard schedule. Dose modifications follow the prescribing information when adverse events occur, and tablets must not be split or crushed.

Storage & Sourcing

Store below 30°C in the original blister, protected from moisture, and keep the pack sealed until dispensing. Source from a manufacturer holding GMP certification and provide batch-release documentation with each shipment. Because oncology demand is recurring, distributors benefit from a dependable replenishment schedule and verified cold-chain-free ambient storage. Confirm registration status for the target region before tendering.

FAQ

Q: Why is Sorafenib often combined with TACE rather than used alone? A: Embolization cuts the tumor's arterial supply locally while Sorafenib suppresses residual angiogenic and proliferative signaling systemically, addressing the disease on two fronts.

Q: How many tablets does a monthly course require? A: At 400mg twice daily using 200mg tablets, a patient takes four tablets per day, so the 120-tablet pack covers about one month of continuous therapy.

Q: What documentation should a B2B oncology buyer request? A: Request GMP certification, batch-release papers and confirmation of the product's registration for the intended indication and market before placing a recurring order.